Akebia Therapeutics (AKBA) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 25, 2023 8:09 AM EDTAkebia to host conference call on August 25, 2023 at 9:00 a.m. ET
Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023Reports Auryxia® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net product revenue guidance of $175.0-$180.0 millionCAMBRIDGE, Mass., Aug. 25, 2023 /PRNewswire/... More
